Home › Companies › SABS

SAB Biotherapeutics

SABS Lead: Phase 2 1 Biotech Distilled article ↓

Metabolic Protein

Most recent annual filing: 2026-03-09

Pipeline (1 active programs)

SAB-142

Protein Target: thymocytes, T-lymphocytes, CD4+ T cells, CD8+ T cells

Type 1 Diabetes Phase 2 intravenous

Technology platforms

Tc-Bovine

Transchromosomic cattle platform using engineered human artificial chromosomes to produce targeted, multi-specific human IgG (hIgG) polyclonal antibodies at scale without human plasma donors; applicable to immune/autoimmune disorders, cancer, viruses, bacteria, and toxins

Biotech Distilled coverage (1)

2026-07-16 SAB Biotherapeutics (SABS) — Scientific Deep Dive for SAB-142 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.